Loading
A phase 2 trial of camrelizumab, rivoceranib (apatinib), nab-paclitaxel, epirubicin and other drugs in triple-negative breast cancer, run by West China Hospital, now recruiting.
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) is a phase 2, interventional study registered as NCT05447702 by West China Hospital, with a registry enrolment figure of 35 participants, started 2022-11-01 and due to reach its primary completion in 2023-12-31. Interventions recorded: Camrelizumab; Apatinib; Nab-paclitaxel; Epirubicin; Cyclophosphamide. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Camrelizumab, Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Rivoceranib (apatinib), Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Rivoceranib (apatinib), Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Rivoceranib (apatinib), Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/